Fore Biotherapeutics
PrivateLast Round
Series D-2
Extension
Jul 7, 2026
Est. Valuation
$75M
Total Funding Raised
$249.9M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Fore Biotherapeutics operates in Healthcare & Life Sciences and is based in Philadelphia, Pennsylvania. Its latest recorded funding round was a Series D-2 Extension round in July 2026.
Fore Biotherapeutics is a biotechnology company that develops precision oncology therapies for patients with rare, unaddressed tumor mutations.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Fore Biotherapeutics Comparables
Compare Fore Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Erasca | 78% | |
| C4 Therapeutics | 74% | |
| Roche Holding | 72% |
For institutional investors. Book with your work email.
Fore Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D-2 Extension | Jul 7, 2026 | ||||
| Series D | May 22, 2025 | ||||
| Series D | Aug 23, 2023 | ||||
| Series C | Sep 21, 2020 | ||||
| VC Round | Apr 30, 2018 | ||||
Series A | Jun 22, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Fore Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SymBiosis Capital Management | Series D-2 Extension |
| Samsung Securities Co., Ltd. | Series D, Series D-2 Extension |
| TaiAx Capital | Series D-2 Extension |
| Bio Capital Impact Fund | VC Round |
| Cormorant Asset Management | Series D, Series C, Series D-2 Extension |
| 3B FUTURE Health Fund | Series D, Series D-2 Extension, VC Round |
| Pontifax Venture Capital | VC Round, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 80% MoM, from 2.2K to 4K.
- Jul 7, 2026
$67M round led by Medicxi, SR One, and SymBiosis Capital Management.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 11, 2026
Fore Biotherapeutics Inc. is scheduled to present its corporate strategy and discuss its lead cancer drug plixorafenib at the Morgan Stanley 24th Annual Global Healthcare Conference in Pennsylvania on Sep 15th '26.
- receives_financingAug 6, 2026
In May '26, Fore Biotherapeutics Inc. closes a $38M extension of its Series D in Pennsylvania, bringing its total funding to more than $180M over the previous three years.
For institutional investors. Book with your work email.
Fore Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Fore Biotherapeutics's valuation, stock price, and market status.
Is Fore Biotherapeutics a public or private company?
Fore Biotherapeutics is a private company.
What is the current stock price of Fore Biotherapeutics?
Fore Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Fore Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Fore Biotherapeutics worth (valuation)?
Fore Biotherapeutics's valuation is estimated at $75.0M based on funding round data.
Can I buy Fore Biotherapeutics stock?
Fore Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Fore Biotherapeutics's last funding round?
Fore Biotherapeutics's most recent funding round was Series D-2 Extension on July 7, 2026.
Who are the main investors in Fore Biotherapeutics?
Key investors in Fore Biotherapeutics include SymBiosis Capital Management, Pontifax Venture Capital, OrbiMed, SR One, Medicxi.
Will Fore Biotherapeutics IPO soon?
No public IPO plans have been announced for Fore Biotherapeutics.
How can I track Fore Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Fore Biotherapeutics's shares on secondary markets.